DDrare: Database of Drug Development for Rare Diseases

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 250 mg CK-2017357; 3,4-DAP; 3,4-Diaminopyridine; 3,4-diaminopyridine; 500 mg CK-2017357; ALXN1210; AMIFAMPRIDINA; AMIFAMPRIDINE; ARGX-113; ATG (rabbit); AZA; Abatacept; Abatacept Injection; Acetaminophen; Amifampridine; Amifampridine Phosphate; Anti-C5 antibody; Anti-Thymocyte Globulin; Azathioprine; B-peptide-CRM197 conjugate; BBR 2778; BELIMUMAB; BENLYSTA® (belimumab); BORTEZOMIB; Belimumab; Benlysta (belimumab); Bortezomib; CD19-directed humanised afucosylated monoclonal antibody; CELLCEPT; CFZ533; CV-MG01; Carmustine; CellCept; CellCept 500 mg; CellCept 500 mg film-coated tablets; CellCept 500 mg tablets; CellCept®500 mg tablets; Cellcept; Cellcept 500 mg tablets; Chloride; Cyclophosphamide; Cyclosporine; Cytarabine; DAP; DAS-001; DIFENIDRAMINA CLORIDRATO; Descartes-08; Difenidramina; Diphenhydramine; Diphenhydramine hydrochloride; ECULIZUMAB; EFALIZUMAB; EN101; EPHEDRINE HYDROCHLORIDE; Eculizumab; Efalizumab; Efedrina; Efgartigimod; Ephedrine; Etoposide; FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE; FIRDAPSE 10mg Tablets; Fc- and CDR-modified humanised monoclonal antibody against C5; Firdapse; G-CSF; GAMUNEX 10%; GB-0998 (Intravenous immunoglobulin); GSK1550188; Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); HBM9161 Injection (340 mg); HBM9161 Injection (680mg and 340 mg); HIZENTRA ®; HUMAN NORMAL IMMUNOGLOBULIN (IV); Hematopoietic Stem Cell Transplantation; Hidrocloruro de efedrina; Human normal immunoglobulin; Human normal immunoglobulin G (IgG); IGIV-C; IMMUNOGLOBULIN G; INEBILIZUMAB; IVIG; IVIg; Immune Globulin (Human), 10% Caprylate/Chromatography Purified; Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C); Immune globulin; Inebilizumab; Influenza vaccine; Intravenous ImmuneGlobulin; Leflunomide; M281; M281 Injection; METILPREDNISOLONE; MONARSEN; MONITOR; MabThera; Mabthera; Magnesium; Magnesium sulfate; Melphalan; Mesna; Mestinon; Methotrexate; Methylprednisolone; Metilprdnisolone; Mutagrip; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; Mycophenolate mofetil (CellCept); Mycophenolate mofetil [CellCept]; Mycophenolic acid; Other: Laboratory Biomarker Analysis; PARACETAMOLO; PIXANTRONE; PRIVIGEN; PYRIDOSTIGMINE; Paracetamolo; Phosphate; Pixantrone; Prednisolone; Prednisone; Prednisone - Azathioprine; Prednisone alone; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Procedure: PLEX; Procedure: Peripheral Blood Stem Cell Transplantation; Procedure: Plasmapheresis; Procedure: Syngeneic Bone Marrow Transplantation; Procedure: thymectomy plus prednisone; Pyridostigmine; RC18 160mg; RC18 240 mg; RITUXIMAB; ROZANOLIXIZUMAB; RTX; RVT-1401; Rabbit; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Ravulizumab; Rituximab; Rituximab (Rituxan); Rozanolixizumab; SALBUTAMOL SULFATE PH. EUR.; SOLIRIS; Salbutamol; Salbutamol 4Mg Tablet; Salbutamol WZF 4 mg; Sodium Chloride solution; Sodium chloride; Soliris; Subcutaneous immunoglobulins; Sulfate; Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil); Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg); T-peptide-CRM197 conjugate; TAK-079; Tacrolimus; Tacrolimus capsule; Tetanus vaccin; Tofacitinib; Tofacitinib 5 MG; UCB7665; Ultomiris; Velcade; Velcade®; Zilucoplan; Zilucoplan (RA101495); [M281]; [NA]; [TAK-079, TSF-021, TSF79]; [acetominofene]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02950155 (ClinicalTrials.gov)	October 16, 2016	28/10/2016	A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis	A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)	Generalized Myasthenia Gravis	Drug: Rituximab;Drug: Sodium Chloride solution	Fredrik Piehl	NULL	Active, not recruiting	18 Years	N/A	All	47	Phase 3	Sweden
2	EUCTR2015-005749-30-SE (EUCTR)	23/06/2016	28/04/2016	A clinical trial investigating the effect and safety of the drug rituximab in patients with new onset myasthenia gravis, an autoimmune condition affecting muscle strenght	A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study - Rinomax	New onset myasthenia gravis MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera INN or Proposed INN: RITUXIMAB	Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	Sweden
3	JPRN-UMIN000016564	2015/03/13	23/02/2015	Rituximab for intractable myasthenia gravis		myasthenia gravis	rituximab	Tokushima University Hospital	NULL	Pending	15years-old	80years-old	Male and Female	1	Not selected	Japan
4	NCT02110706 (ClinicalTrials.gov)	May 2014	7/4/2014	BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis	B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis	Myasthenia Gravis	Drug: Rituximab;Drug: Placebo	Yale University	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	21 Years	90 Years	All	52	Phase 2	United States
5	JPRN-UMIN000012089	2013/10/15	23/10/2013	Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study	Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study - Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study	MuSK antibody-positive myasthenia gravis	Administration of Rituximab at the standard dose of 375 mg/m2 every week for 4 consecutive weeks and then monthly for the next 3 months.	Department of NeurologyUniversity of Tokyo, Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	5	Not selected	Japan
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00774462 (ClinicalTrials.gov)	January 2008	16/10/2008	Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis	FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis	Myositis;Myasthenia Gravis	Drug: Rituximab	Assistance Publique - Hôpitaux de Paris	Institut National de la Santé Et de la Recherche Médicale, France;Roche Pharma AG	Completed	18 Years	80 Years	Both	30	Phase 2	France
7	NCT00619671 (ClinicalTrials.gov)	April 2004	14/1/2008	A Pilot Trial of Rituxan in Refractory Myasthenia Gravis	Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.	Refractory Myasthenia Gravis	Drug: Rituximab (Rituxan)	University of Vermont	Genentech, Inc.	Completed	18 Years	80 Years	Both	10	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02950155
(ClinicalTrials.gov)

October 16, 2016

28/10/2016

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)

Generalized Myasthenia Gravis

Drug: Rituximab;Drug: Sodium Chloride solution

Fredrik Piehl

NULL

Active, not recruiting

18 Years

N/A

All

Phase 3

Sweden

EUCTR2015-005749-30-SE
(EUCTR)

23/06/2016

28/04/2016

A clinical trial investigating the effect and safety of the drug rituximab in patients with new onset myasthenia gravis, an autoimmune condition affecting muscle strenght

A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study - Rinomax

New onset myasthenia gravis
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Mabthera
INN or Proposed INN: RITUXIMAB

Karolinska Institutet

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

Sweden

JPRN-UMIN000016564

2015/03/13

23/02/2015

Rituximab for intractable myasthenia gravis

myasthenia gravis

rituximab

Tokushima University Hospital

NULL

Pending

15years-old

80years-old

Male and Female

Not selected

Japan

NCT02110706
(ClinicalTrials.gov)

May 2014

7/4/2014

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis

Myasthenia Gravis

Drug: Rituximab;Drug: Placebo

Yale University

National Institute of Neurological Disorders and Stroke (NINDS)

Completed

21 Years

90 Years

All

Phase 2

United States

JPRN-UMIN000012089

2013/10/15

23/10/2013

Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study

Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study - Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study

MuSK antibody-positive myasthenia gravis

Administration of Rituximab at the standard dose of 375 mg/m2 every week for 4 consecutive weeks and then monthly for the next 3 months.

Department of NeurologyUniversity of Tokyo, Graduate School of Medicine

NULL

Complete: follow-up complete

20years-old

80years-old

Male and Female

Not selected

Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00774462
(ClinicalTrials.gov)

January 2008

16/10/2008

Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis

FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis

Myositis;Myasthenia Gravis

Drug: Rituximab

Assistance Publique - Hôpitaux de Paris

Institut National de la Santé Et de la Recherche Médicale, France;Roche Pharma AG

Completed

18 Years

80 Years

Both

Phase 2

France

NCT00619671
(ClinicalTrials.gov)

April 2004

14/1/2008

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.

Refractory Myasthenia Gravis

Drug: Rituximab (Rituxan)

University of Vermont

Genentech, Inc.

Completed

18 Years

80 Years

Both

Phase 1;Phase 2

United States